Chamber and committees

The number of people diagnosed with Psoriatic Arthritis in each NHS Board is not held centrally. The following table shows patients who have been admitted to hospital with a diagnosis of Psoriatic Arthritis in each calendar year since 1999. However this is likely to underestimate the total number since many cases will be treated in a primary care setting only.

Source: SMR01,ISD Scotland

*Following ISD Statistical Disclosure Control Protocol, any cells with count values of 4 or less have been suppressed in order to protect the confidentiality of potentially personally identifiable information.

1. A full list of the ICD10 diagnosis codes used to identify patients can be found in the attached notes.

Notes:

1. Up to six diagnoses (one principal diagnosis and five secondary diagnoses) may be recorded per hospital episode, using the International Classification of Disease Codes, Tenth Revision (ICD-10). All six diagnostic positions were used to identify the relevant cases.

2. The primary diagnosis is defined as the main condition treated or investigated during the relevant episode of healthcare. The five secondary diagnoses describe other conditions which the patient may have.

3. The following paired ICD10 codes were used to identify the relevant cases 'L40.5 D' + any of the following:

'M07.0 A'

'M07.1 A'

'M07.2 A'

'M07.3 A'

'M09.0 A' (Juvenile)

Scottish Government investment in cancer research is primarily through the Chief Scientist Office (CSO). CSO supports cancer research through a number of mechanisms. These are:

• Over £40 million annually in the NHS to meet the additional costs of hosting research. Of this around £10 million per annum supporting the cost of cancer research (including research into rare tumours) carried out in the NHS. This figure is not routinely broken down into tumour type.

• CSO invests £350,000 per annum in the Experimental Cancer Medicine Centres Network (in collaboration with a number of other funders) to assist in delivery of early phase cancer studies. This figure is not broken down into tumour type

• CSO also invests £438,000 annually in the Scottish Cancer Research Network to increase and sustain clinical trial activity in cancer care. This figure is not broken down into tumor type

• Funding of cancer research studies submitted to the Chief Scientist Office research committees. Applications generated by the research community are assessed based on scientific excellence. The funding level is subject to quality of applications submitted.

An analysis of currently active studies funded though the CSO committees shows that the following amounts have been committed for projects specifically aimed at rare cancers. The definition of rare is a tumour not included in the 10 most common cancers listed by incidence in the ISD report Cancer Incidence in Scotland (2014) published on May 17 2016.

Classical Hodgkin Lymphoma £226,312

Malignant Pleural Mesothelioma £194,556

Oesophagogastric Carcinoma £143,624

Acute Lymphoblastic Leukaemia £176,624

Glioblastoma £174,582

Further indirect support is provided through an annual contribution (currently around £10 million) from CSO to the major National Institute for Health Research programmes that cover a broad range of health research including cancer research across the UK

Information collected by National Records of Scotland is set out in the following table.

Deaths where Alcoholic Liver Disease [1] was the underlying cause, Scotland, 1999 to 2015

[1] Deaths classified under the International Classification of Diseases. 1999 figures based on the 9^th revision (ICD-9) using codes 571.0 to 571.3. 2000 figures onwards based on 10^th revision (ICD-10) using code K70.

[2] Deaths registered during the calendar year.

I refer the member to the Scottish Government website where marketing spend for 2014-15 and 2015-16 was published on 1 November 2016. Please see the following links:

https://beta.gov.scot/publications/advertising-spend-2015-2016/

https://beta.gov.scot/publications/advertising-spend-2014-2015/

The Scottish Government’s award-winning marketing promotes Scotland around the world as a modern, creative and dynamic nation; and helps people in Scotland make informed choices, improve their opportunities and understand the positive role of public services in their lives.

Our marketing work is an integral part of our life-saving and improving campaigns. For example, our Detect Cancer Early campaign resulted in an 8% increase in early stage diagnosis of breast, lung and colorectal cancers from baseline and a 35.6% increase in proportion of lung cancers diagnosed at the earliest stage, alongside a 50% increase in women consulting their GP with breast symptoms and increased uptake of the national bowel screening programme.

However, we continue to pursue cost-effective means of public engagement, and have cut marketing costs by 12% in the last year.

Our ‘Beating Cancer: Ambition and Action’ strategy and the accompanying £100 million investment over five years, serves as a blueprint for the future of cancer services in Scotland, improving the prevention, detection, diagnosis, treatment and aftercare of people affected by all types of cancer.

NHS Scotland operates independently from the rest of the UK and does not refer to Never Events for data capturing purposes.

We will be considering any funding implications as part of the development and delivery of our strategic approach to social isolation. No decisions on funding for the Social Isolation and Loneliness Fund have been made beyond 2016-17.

It is not possible to say how many people have ceased drug use completely since the publication of The Road to Recovery as this information is not held centrally. The Scottish Government is currently working closely with Information Services Division Scotland, national commissioned organisations, ADPs and services to develop a new data collection system (Drug and Alcohol Information System ) which will collect and report on drug and alcohol treatment and outcomes information, including abstinence.

Recovery for some individuals is not the same as abstinence. The Road to Recovery set out the importance of developing a system of care which ensured that individuals were offered a treatment and recovery package that best met their needs and aspirations.

Decisions on the type of Opioid Replacement Therapy (ORT), including methadone, to prescribe are for clinicians, in close discussion with their clients. The use of ORT is done in line with UK guidelines on the Clinical Management of Drug Misuse and Dependence. These guidelines state that for those individuals who are in receipt of longer-term prescriptions, that they should be reviewed at regular intervals (usually at least three-monthly), and should be part of a broader programme of care planned social and psychological support.

Scottish Government analysts have been working with NHS Health Scotland on a review of evidence on social isolation and loneliness. This will help identify the adequacy of data collection in this area and will feed into our strategic approach to social isolation, which will be developed over 2017. We plan to consult with stakeholders in early 2017.